Compass therapeutics appoints biopharmaceutical industry leader barry shin as chief financial officer

Boston, dec. 10, 2024 (globe newswire) -- compass therapeutics, inc. (nasdaq: cmpx), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the appointment of barry shin as chief financial officer, as of december 9, 2024. mr. shin is a veteran biopharmaceutical leader with over 20 years of experience as a finance and operations executive, investment banker, and corporate advisor.
CMPX Ratings Summary
CMPX Quant Ranking